Topical Hydromorphone for Wound Healing

Status

Terminated

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00177060

Enrollment

Registered

2005-09-15

Start date

2003-10-31

Completion date

2007-05-31

Last updated

2010-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound Healing

Brief summary

The hypothesis is that topical opioids will hasten wound healing in humans.

Detailed description

This is based on our published data that morphine is a powerful stimulant of angiogenesis and our preclinical study of wounds in rats which demonstrate that topical opioids (morphine, hydromorphone and fentanyl) hasten healing of punch biopsy wounds. This study will focus on hydromorphone which was more powerful than morphine as a wound-healer in the rat study.

Interventions

DRUGhydromorphone

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Self-identified as normal, healthy volunteers age 18-65.

Exclusion criteria

* Known bleeding disorder.

Design outcomes

Primary

Measure	Time frame
Healing rates and microvessel density will be compared statistically for the control-ointment versus hydromorphone-ointment subjects.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026